Myldrox (Meldonium Dihydrate)

Meldonium Dihydrate, the active ingredient in Myldrox, is a metabolic modulator presented as an intravenous solution for intravenous use. It is used to support cardiac energy metabolism in patients with certain cardiovascular conditions. GNH USA supplies Myldrox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meldonium Dihydrate is employed in cardiovascular conditions that involve impaired myocardial energy metabolism.

- Ischemic heart disease: improves myocardial energy efficiency and may reduce angina episodes. - Heart failure: supports cardiac contractility by shifting metabolism toward glucose utilization. - Peripheral vascular disease: enhances tissue perfusion by optimizing cellular energy production.

Meldonium Dihydrate may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Dizziness: may occur during infusion. - Insomnia: difficulty initiating sleep. - Mild hypotension: transient blood pressure drop. - Injection site irritation: redness or discomfort.

Serious or Rare Side Effects: - Arrhythmia: abnormal heart rhythm. - Severe hypotension: marked blood pressure reduction. - Anaphylactic reaction: signs of severe allergy. - Elevated liver enzymes: possible hepatic involvement. - Renal impairment: reduced kidney function. - Thrombocytopenia: low platelet count.

When using Meldonium Dihydrate, consider the following precautions to ensure safe administration.

- Cardiovascular assessment: evaluate baseline cardiac function. - Blood pressure monitoring: watch for hypotensive episodes. - Renal function: assess creatinine clearance before infusion. - Pregnancy safety: avoid use unless benefits outweigh risks. - Concomitant drugs: review for agents affecting carnitine metabolism. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Meldonium Dihydrate can interact with other medicines; the interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP450 inhibitors: may increase Meldonium exposure. - Anticoagulants: heightened risk of bleeding. - Other metabolic modulators: additive effects on energy pathways.

Moderate Interactions (Monitor Closely): - Beta‑blockers: potential additive hypotensive effect. - Diuretics: monitor electrolyte balance. - Statins: observe for muscle-related side effects.